These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20877301)

  • 41. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia.
    Ollendorf DA; Joyce AT; Rucker M
    MedGenMed; 2004 Jan; 6(1):5. PubMed ID: 15208518
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Polymorphisms in lipid metabolism related miRNA binding sites and risk of metabolic syndrome.
    Ye Q; Zhao X; Xu K; Li Q; Cheng J; Gao Y; Du J; Shi H; Zhou L
    Gene; 2013 Oct; 528(2):132-8. PubMed ID: 23911300
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabolic syndrome in drug-naïve first-episode psychosis treated with atypical antipsychotics.
    Sahoo S; Ameen S; Akhtar S
    Aust N Z J Psychiatry; 2007 Jul; 41(7):629. PubMed ID: 17691161
    [No Abstract]   [Full Text] [Related]  

  • 44. Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
    Houston JP; Kohler J; Bishop JR; Ellingrod VL; Ostbye KM; Zhao F; Conley RR; Poole Hoffmann V; Fijal BA
    J Clin Psychiatry; 2012 Aug; 73(8):1077-86. PubMed ID: 22967772
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Insulin receptor, IRS1, IRS2, INSIG1, INSIG2, RRAD, and BAIAP2 gene expressions in glioma U87 cells with ERN1 loss of function: effect of hypoxia and glutamine or glucose deprivation.
    Minchenko DO; Kharkova AP; Hubenia OV; Minchenko OH
    Endocr Regul; 2013 Jan; 47(1):15-26. PubMed ID: 23363253
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies.
    Bou Khalil R
    Clin Neuropharmacol; 2012; 35(3):141-7. PubMed ID: 22592510
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.
    Ruaño G; Goethe JW; Caley C; Woolley S; Holford TR; Kocherla M; Windemuth A; de Leon J
    Mol Psychiatry; 2007 May; 12(5):474-82. PubMed ID: 17199131
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genetic variants of matrix metalloproteinase (MMP2) gene influence metabolic syndrome susceptibility.
    Yadav SS; Mandal RK; Singh MK; Usman K; Khattri S
    Genet Test Mol Biomarkers; 2014 Feb; 18(2):88-92. PubMed ID: 24192303
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: a six-week prospective study in Indian female patients.
    Saddichha S; Ameen S; Akhtar S
    Schizophr Res; 2007 Sep; 95(1-3):247. PubMed ID: 17644311
    [No Abstract]   [Full Text] [Related]  

  • 51. CNR1 gene and risk of the metabolic syndrome in patients with schizophrenia.
    Yu W; De Hert M; Moons T; Claes SJ; Correll CU; van Winkel R
    J Clin Psychopharmacol; 2013 Apr; 33(2):186-92. PubMed ID: 23422373
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Atypical antipsychotics related metabolic syndrome in bipolar patients.
    Yumru M; Savas HA; Kurt E; Kaya MC; Selek S; Savas E; Oral ET; Atagun I
    J Affect Disord; 2007 Mar; 98(3):247-52. PubMed ID: 16970993
    [TBL] [Abstract][Full Text] [Related]  

  • 53. No association between genetic or epigenetic variation in insulin growth factors and antipsychotic-induced metabolic disturbances in a cross-sectional sample.
    Moons T; De Hert M; Kenis G; Viechtbauer W; van Os J; Gohlke H; Claes S; van Winkel R
    Pharmacogenomics; 2014 May; 15(7):951-62. PubMed ID: 24956249
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interactions among genetic variants from SREBP2 activating-related pathway on risk of coronary heart disease in Chinese Han population.
    Liu X; Li Y; Lu X; Wang L; Zhao Q; Yang W; Huang J; Cao J; Li H; Gu D
    Atherosclerosis; 2010 Feb; 208(2):421-6. PubMed ID: 19740467
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs.
    Moons T; Claes S; Martens GJ; Peuskens J; Van Loo KM; Van Schijndel JE; De Hert M; van Winkel R
    Schizophr Res; 2011 Feb; 125(2-3):187-93. PubMed ID: 21050724
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of effects of olanzapine and risperidone on body mass index and blood sugar level in schizophrenic patients.
    Ingole S; Belorkar NR; Waradkar P; Shrivastava M
    Indian J Physiol Pharmacol; 2009; 53(1):47-54. PubMed ID: 19810576
    [TBL] [Abstract][Full Text] [Related]  

  • 57. No association between polymorphisms in the INSIG1 gene and the risk of type 2 diabetes and related traits.
    Szopa M; Meirhaeghe A; Luan J; Moreno LA; Gonzalez-Gross M; Vidal-Puig A; Cooper C; Hagen R; Amouyel P; Wareham NJ; Loos RJ
    Am J Clin Nutr; 2010 Jul; 92(1):252-7. PubMed ID: 20444954
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Two candidate genes (FTO and INSIG2) for fat accumulation in four canids: chromosome mapping, gene polymorphisms and association studies of body and skin weight of red foxes.
    Grzes M; Szczerbal I; Fijak-Nowak H; Szydlowski M; Switonski M
    Cytogenet Genome Res; 2011; 135(1):25-32. PubMed ID: 21846970
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review.
    De Hert M; Schreurs V; Sweers K; Van Eyck D; Hanssens L; Sinko S; Wampers M; Scheen A; Peuskens J; van Winkel R
    Schizophr Res; 2008 Apr; 101(1-3):295-303. PubMed ID: 18299188
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-Term Treatment with Olanzapine in Hospital Conditions: Prevalence and Predictors of the Metabolic Syndrome.
    Popović I; Ravanić D; Janković S; Milovanović D; Folić M; Stanojević A; Nenadović M; Ilić M
    Srp Arh Celok Lek; 2015; 143(11-12):712-8. PubMed ID: 26946767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.